Sanofi Appoints Dr. Gary J. Nabel as Chairman of the Strategic Development and Scientific Advisory Council

PR Newswire/Les Echos/ 
    Sanofi Appoints Dr. Gary J. Nabel as Chairman of the Strategic  
              Development and Scientific Advisory Council 
Paris, France - January 7, 2013 - Sanofi (EURONEXT : SAN ; NYSE : SNY) is
pleased to announce today the appointment of Dr. Gary J. Nabel, M.D., Ph.D., 
to Chairman of the Strategic Development and Scientific Advisory Council 
Dr. Nabel, currently Senior Vice President, Chief Scientific Officer and 
Deputy to Dr. Elias Zerhouni, President, Global R&D, will succeed Dr. Richard 
Klausner. As part of his key responsibilities as Chief Scientific Officer for 
global R&D, Dr. Nabel will direct the activities of the Council, including 
selection, appointment and evaluation of advisers. 
"I am delighted that Dr. Gary Nabel will continue to make this Council a vital
part of our efforts to open Sanofi's research and development to outside
perspectives", said Dr. Elias Zerhouni, President, Global R&D, Sanofi. "I also
wish to recognize and warmly thank Dr. Richard Klausner who has been an
outstanding adviser to the Council. Under his leadership and invaluable
experience, he has played a key role in setting out the role and composition 
of a group of experienced and internationally recognized advisers." 
Created in November 2010, the Council is a unique structure developed to 
enhance scientific discovery in a collaborative approach and to further 
develop a truly world-class research and development platform for future 
innovation for the benefit of patients around the world. The role of the 
Council is to advise Sanofi on new and emerging areas of science and 
technology as well as deepen Sanofi relationship with the external scientific 
world by creating a strong network of scientists and institutional 
partnerships. Dr. Richard Klausner occupied this position since March 1, 2011, 
providing overall direction and scientific leadership together with some of 
the most talented scientists around the world across the continuum from 
Discovery to Development to Delivery. 
Dr. Gary J. Nabel Biography
Dr. Nabel has an extensive and distinguished background of academic and 
hospital appointments, and committee memberships including numerous 
prestigious awards and honors and an extensive publication record. He 
graduated magna cum laude from Harvard College in 1975 and continued his 
graduate studies at Harvard University, completing his Ph.D. in 1980 and his 
M.D. in 1982. He served as a postdoctoral fellow in the laboratory of David 
Baltimore at MIT's Whitehead Institute. Before his appointment at the Vaccine 
Research Center, Dr. Nabel served as the Henry Sewall Professor of Internal 
Medicine, Professor of Biochemistry, and Howard Hughes Medical Institute 
Investigator at the University of Michigan in Ann Arbor. In addition to his 
faculty positions, Dr. Nabel also served as the Director of the Center for 
Gene Therapy and co-director of the Center for Molecular Medicine at the 
University of Michigan. In recognition of his expertise at the forefront of 
virology, immunology, gene therapy, and molecular biology, Dr. Nabel was 
elected as a member of the Institute of Medicine of the National Academy of 
Sciences in 1998. 
Dr. Richard Klausner Biography
Dr. Klausner is the former Executive Director for Global Health of the Bill 
and Melinda Gates Foundation. He was Director of the National Cancer Institute 
(NCI) between 1995 and 2001. He is currently partner at the Column Group, a 
San Francisco based venture firm. His research has been recognized with awards
including the Outstanding Investigator Award from the American Federation of
Clinical Research and the William Damashek Prize for major discoveries in
haematology. He received the 1997-1998 Dickson Prize in Medicine and the 1998
Raymond Bourgine Award. He has served as an Advisor to the Presidents of the
Academies on counterterrorism and as Liaison to the White House Office of
Science & Technology Policy. He is a member of the National Academy of 
Sciences, the Institute of Medicine and the American Academy of Arts and 
Sciences. Dr. Klausner is a past president of the American Society of Clinical 
Investigation and has been Chairman of the National Science Education 
Standards Projects of the National Academy of Sciences. 
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY). 
Media Relations                 Investor Relations
Jean-Marc Podvin                Sébastien Martel
Tel.: + (33) 1 53 77 46 46      Tel.: + (33) 1 53 77 45 45          
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Jan/07/2013 08:01 GMT
Press spacebar to pause and continue. Press esc to stop.